Waxman Report Showing FDA Pre-emption Split May Alter Legal Debate
This article was originally published in The Tan Sheet
Executive Summary
A report from influential House leader Henry Waxman exposes a rift between senior FDA staff and the agency's Office of Chief Counsel that could help the plaintiff in the FDA pre-emption case that has reached the Supreme Court
You may also be interested in...
Drug Industry Braces For Supreme Court Ruling In Wyeth Pre-emption Case
This week everyone's attention is riveted on the presidential election. But for the pharmaceutical industry there is another issue just as compelling. On Nov. 3, the U.S. Supreme Court will hear oral arguments in the case that will decide the future of product liability litigation
Drug Industry Braces For Supreme Court Ruling In Wyeth Pre-emption Case
This week everyone's attention is riveted on the presidential election. But for the pharmaceutical industry there is another issue just as compelling. On Nov. 3, the U.S. Supreme Court will hear oral arguments in the case that will decide the future of product liability litigation
Drug Industry Braces For Supreme Court Ruling In Wyeth Pre-emption Case
This week everyone's attention is riveted on the presidential election. But for the pharmaceutical industry there is another issue just as compelling. On Nov. 3, the U.S. Supreme Court will hear oral arguments in the case that will decide the future of product liability litigation